America Imports the World's Drug Prices

Alvotech specializes in complex biosimilars and should gain bargaining power as payers demand substitutable versions of costly biologic blockbusters.

Celltrion is a global biosimilar specialist positioned to gain adoption as reference pricing increases pressure to switch away from originator biologics.

Elevance and its CarelonRx pharmacy-benefit operation stand to benefit from lower branded-drug reimbursement and stronger access to generic and biosimilar substitutes.

Formycon's focused biosimilar pipeline directly addresses high-cost branded biologics whose economics are threatened by stricter price comparisons.

Hikma's injectable and oral generic portfolios position it to capture volume as US purchasers intensify substitution toward lower-cost medicines.

Aurobindo's large US generics business and injectable portfolio can gain volume as reference pricing increases pressure to adopt lower-cost alternatives.

Samsung Biologics combines large-scale biologics manufacturing with Samsung Bioepis's biosimilars, supporting lower-cost alternatives across blockbuster categories.

Reference pricing increases demand for biosimilars and generics that can establish a defensible lower-cost benchmark.

Its global portfolio of generics and biosimilars gives payers credible lower-cost substitutes as reference pricing increases pressure on patented-drug spending.

Fresenius benefits through Fresenius Kabi's generic injectables and biosimilars, which offer health systems practical tools for reducing branded-drug spending.

Large gaps between US and European obesity-drug prices make Novo Nordisk a prominent reference-pricing target.

UCB's patented neurology and immunology products are internationally commercialized specialty medicines vulnerable to lower US benchmark prices.

Chugai’s portfolio of patented oncology, immunology and rare-disease medicines leaves its blockbuster economics exposed if U.S. reimbursement is benchmarked against lower developed-market prices.

Lower realized prices would compound the pressure from looming patent expirations across its mature blockbuster portfolio.

Ipsen's concentrated oncology and rare-disease portfolio depends on premium branded pricing and has limited insulation from international benchmarking.

Vertex's highly profitable cystic-fibrosis franchise illustrates the concentrated blockbuster economics that external reference pricing is designed to restrain.

Bayer's growth drugs, including Nubeqa and Kerendia, face lower lifetime revenue potential if US reimbursement is benchmarked against discounted overseas prices.

Ono's oncology economics include substantial Opdivo-related income and would weaken if reference pricing compresses global blockbuster revenue pools.

Alnylam's high-priced RNA-interference medicines rely on orphan-drug economics that could be diluted if US payers import lower overseas benchmarks.

GSK's patented vaccines, respiratory drugs and specialty medicines could see US margins pressured if lower developed-market prices become binding benchmarks.